AREV Life Sciences Global Corp.
AREVF
$0.01
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -95.30% | -15.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -95.30% | -15.71% |
| Cost of Revenue | -- | -- | -- | 18.55% | -- |
| Gross Profit | -- | -- | -- | -109.38% | -15.71% |
| SG&A Expenses | -100.91% | -89.71% | -70.67% | -139.89% | 8.50% |
| Depreciation & Amortization | -58.63% | -60.69% | -58.20% | -24.82% | -15.31% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -95.11% | -85.84% | -70.90% | -121.74% | 1.45% |
| Operating Income | 94.58% | 85.65% | 70.40% | 138.93% | -3.72% |
| Income Before Tax | 88.29% | 85.15% | 68.92% | -85.28% | -5.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 88.29% | 85.15% | 68.92% | -85.28% | -5.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 88.29% | 85.15% | 68.92% | -85.28% | -5.61% |
| EBIT | 94.58% | 85.65% | 70.40% | 138.93% | -3.72% |
| EBITDA | 101.00% | 86.80% | 71.20% | 151.75% | -8.06% |
| EPS Basic | 88.33% | 86.00% | 72.92% | -96.98% | 13.04% |
| Normalized Basic EPS | 89.47% | 85.60% | 72.22% | 106.47% | 9.52% |
| EPS Diluted | 88.33% | 86.00% | 72.92% | -96.98% | 13.04% |
| Normalized Diluted EPS | 89.47% | 85.60% | 72.22% | 106.47% | 9.52% |
| Average Basic Shares Outstanding | 3.92% | 5.04% | 13.09% | 398.60% | 20.18% |
| Average Diluted Shares Outstanding | 3.92% | 5.04% | 13.09% | 398.60% | 20.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |